With the development of society and the advancement of concepts, men's health has received more and more attention. ED (erectile dysfunction) is considered to be the third biggest killer that threatens men's health after cardiovascular and cerebrovascular diseases and cancer. At the same time, ED is also considered an independent early warning factor for chronic diseases in men, which can predict or trigger many chronic diseases.
It is organized by Yuekang Pharmaceutical Group Co., Ltd. (688658. SH, hereinafter referred to as Yuekang Pharmaceutical) developed the first domestic anti-ED1.1 original research innovative drug Elix ® citrate Aegenafil tablets recently obtained the "Drug Registration Certificate". The drug was led by Guo Yinglu, an academician of the Chinese Academy of Engineering and the leader of the Department of Urology and Andrology in China, to guide the clinical trial. The listing of the drug is considered to be an important milestone in the field of domestic men's health.
On January 18, Yuekang Pharmaceutical held the listing conference and sales signing ceremony of Elix ® citric acid adenafil in Guangzhou, Guangdong Province. Academician Guo Yinglu expressed full affirmation of the listing of Elix ® citric acid adenafil tablets. He said that the listing of Elix ® citrate adenafil tablets has made a positive contribution to promoting the cause of men's health and is a remarkable "Chinese innovation".
Full coverage of sales channels
According to data from the intranet, in 2020, the data of China's public medical institutions and retail terminals of physical pharmacies in Chinese cities show that the main anti-ED chemical drugs in China are sildenafil citrate tablets, tadalafil tablets, valdinafine hydrochloride tablets and other products, with a market size of 3.567 billion yuan in 2020. As ED diseases are more and more valued, the market space for this drug is constantly expanding.
Yuekang Pharmaceutical is also increasing the construction of sales channels. At present, the company has made strong efforts in the four major sales channels of online e-commerce channels, OTC market, third terminal and hospital market. In terms of network e-commerce, Yuekang Pharmaceutical has reached a cooperation intention with well-known e-commerce platforms such as Jingdong Health, Ali Health, Meituan, Dingdang Drug Delivery, etc., fully covering domestic network sales channels, and the current sales growth rate of "Na fei" products is very fast; in addition, the company continues to expand OTC channels to explore new tracks for new product promotion; in terms of cooperation with dealers, Yuekang Pharmaceutical has reached preliminary cooperation intentions with dealers in more than 20 provinces and cities; in the hospital market, the company will further strengthen academic promotion activities. Through the recognition of experts and doctors, expand the popularity of the new brand "Alex" among consumers.
At the press conference, Yuekang Pharmaceutical reached strategic cooperation with many channel providers to lay out the development of the whole industry chain. At the press conference, a total of 4 rounds of signing were carried out, and 60 channel providers signed cooperation agreements with Yuekang Pharmaceutical. These include 1 major e-commerce platforms such as Yaowang, Ark Jianke, Baidu Health, Ali Health Pharmacy, Dingdang Fast Medicine and so on. In terms of offline terminal channels, Yuekang Pharmaceutical has signed cooperation agreements with 60 channel providers such as The People's Pharmacy and Yifeng Pharmacy. In the future, Yuekang Pharmaceutical will also carry out strategic cooperation with more valuable and influential channels to jointly create a new pattern of China's anti-ED drug market.
Adhere to hard-core research and development
Mainland innovative drugs are ushering in an explosive period, and Yuekang Pharmaceutical has always adhered to research and development as the core, clinical effects as the guide, and actively promoted the development of innovative drugs in mainland China.
Taking Elix ® citrate adenafil tablets as an example, the drug is the first domestic anti-ED1.1 original research innovative drug, compared with other generic drugs, Elix ® citrate adenafil tablets compound structure design is more stable, the binding rate with the target is higher, with good safety, fast onset, small dose, better drug experience and other characteristics. At present, Elix ® citrate adenafil tablets have been patented in 22 countries and regions around the world.
At the press conference, Deng Chunhua, chairman of the Andrology Society of the Chinese Medical Association, said that Aliss ® citrate edenafil tablets have a new chemical structure, unique pharmacokinetics, clinical research confirmed that it has its own clinical characteristics: good safety, high effectiveness, small impact on diet and other characteristics, is a new weapon for the treatment of diseases in the field of male health. At the same time, he pointed out that ED has become the third largest killer of men's health after cardiovascular and cerebrovascular diseases and cancer, ED is often an independent early warning factor for other chronic diseases, he called on the whole society to pay attention to men's health, do not hide diseases and avoid medical treatment, which is conducive to family health and is also conducive to promoting the development of healthy China.
Yu Weishi, chairman of Yuekang Pharmaceutical, pointed out at the meeting that the birth of Elix ® citric acid adenafil is a milestone in the development process of Yuekang, in addition, Yuekang's existing focus is on 13 new drugs of class 1 under research, and a number of blockbuster products are expected to accelerate the listing. In the future, Yuekang Pharmaceutical will focus on cardiovascular and cerebrovascular, anti-tumor, infectious diseases and other advantageous areas, actively explore innovative products, and come up with a large number of excellent and good products to return patients, investors and society.
Edit: Lin Sen